The increasing emphasis on evidence in international health care has profound implications for companies in the life sciences industries, informing their approach to market access and driving their strategies with regard to outcomes research, pricing, and reimbursement.Our consultants have contributed to various discussions about evidence – from presenting on comparative effectiveness research at the annual meetings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and other conferences, to addressing the role of evidence in pricing and reimbursement strategies in industry publications and peer-reviewed journals.
There are significant opportunities to integrate market access into product development decisions in early phases. Read about the use of value analytics to forecast market access outcomes and risk-sharing in the pipeline.
Managing Principal Eric Q. Wu and Manager James Signorovitch discuss the methods for indirect comparisons in outcomes research.
Health Care Bulletin: Winter/Spring 2012